Skip to main content
Equibles
PETS logo

PETS · Petmed Express Inc · Metrics

Track PETS — free

Use PETS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PETS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.19 +0.01 (+0.85%) At close · Oct 28 Q1 2027 earnings call transcript
Rebalance outlook locked
Going-concern doubt — cleared Aug 13, 2026

The latest filing states the doubt was alleviated.

“During the three months ended June 30, 2026, management's assessment identified certain conditions and events that, when considered in the aggregate, raised substantial doubt about the Company's ability to continue as a going concern. ... Management determined that these plans are probable of being effectively implemented and are probable of mitigating the conditions that raised substantial doubt. As of the issuance of these financials, management has concluded that substantial doubt about the Company's ability to continue as a going concern for the next twelve months is alleviated by these plans.”
View the 10-Q filed Aug 13, 2026
Market Cap
$25.58M
Shares
21.68M
Volume · Oct 28 18.82K Avg daily vol (3M) 109.94K

PETS metrics

78 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.19
Market cap
$25.58M

Price action

20 metrics
Price change (1W)
-1.7%
Price change (30D)
-16.0%
Price change (3M)
-41.3%
Price change (6M)
-47.6%
Price change (YTD)
-63.1%
Price change (1Y)
-55.6%
Trailing year
Price change (5Y)
-95.5%
52-week high
$3.90
52-week low
$1.15
Change from 52-week high
-69.7%
Change from 52-week low
+2.6%
Annualized volatility
96.7%
Annualized volatility (3M)
39.2%
Beta
1.4
RSI (14D)
31.1
Price vs SMA 50
-22.3%
Price vs SMA 200
-45.0%
Avg volume (3M)
111,402
Relative volume
0.6
Average dollar volume
$175,754

Company

3 metrics
Sector
Healthcare
Industry
Pharmaceutical Retailers
Shares outstanding
21.68M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
0.1×
reciprocal yield 671.5%
P / book
1.1
reciprocal yield 91.4%
FCF yield
—
TTM · current market cap
Buyback yield
0.0%
P / FCF
—
P / operating cash flow
—
Earnings yield
-116.4%

Historical valuation

8 metrics
P / E historical average (3Y)
322.6×
reciprocal yield 0.3%
P / E historical average (5Y)
151.4×
reciprocal yield 0.7%
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-11-10
Last earnings
2026-08-13

Profitability

9 metrics
Gross margin
27.9%
Operating margin
-18.2%
Trailing 12 months
Net margin
-17.3%
Gross profit (TTM)
$47.15M
Operating profit (TTM)
−$30.77M
Net income (TTM)
−$29.28M
Trailing 12 months
Diluted EPS (TTM)
$-1.37
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$7.99
Gross profit per diluted share (TTM)
$2.23
Operating profit per diluted share (TTM)
$-1.46
EBITDA per diluted share (TTM)
$-1.02
Net income per diluted share (TTM)
$-1.39
Operating cash flow per diluted share (TTM)
$-1.12
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
$0.05
Book value per share
$1.35

Growth

11 metrics
Revenue growth YoY
-19.9%
Year over year
Net income growth YoY
—
Revenue (TTM)
$168.86M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+4.5%
Year over year · more shares
Revenue CAGR (3Y)
-10.2%
Revenue CAGR (5Y)
-10.0%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-127.4%
Return on assets
-45.9%
Debt / equity
—
Current ratio
0.7
EBITDA (TTM)
−$21.52M
Free cash flow (TTM)
—
Quick ratio
0.5
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$13.08M
Latest balance sheet
Cash & equivalents
$13.08M
Total assets
$63.76M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$23.81M
Capital expenditures (TTM)
$3.96M
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
$972,000
R&D / revenue
—
Stock compensation / revenue
0.6%

Ownership (13F)

9 metrics
13F filers
49
13F filer change QoQ
-1
Institutional ownership
21.4%
Conviction holders (share of 13F filers)
2.0%
Crowding (high-turnover and private-fund holders)
9.3%
Private-fund adviser ownership
8.9%
Active holders' share change QoQ
-32.6%
Holder tenure
13.9
Price vs estimated holder cost
-50.1%

Ownership (registered funds)

1 metrics
Index-fund ownership
5.7%

Short interest

3 metrics
Short interest
4.1%
Latest settlement · 7.4 days to cover
Days to cover
7.4d
Short-squeeze score
66 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1040130 CUSIP 716382106 13F (30d) 4 filings 4 filers Visit website Investor relations